AI-driven biotechnology company Generate Biomedicines (GENB.US), which focuses on asthma treatment, submitted documents to the U.S. Securities and Exchange Commission on Wednesday, outlining plans to raise up to $100 million through an initial public offering. The company leverages its AI-powered drug discovery platform to develop therapies for severe asthma, with its lead candidate having progressed to a pivotal Phase III clinical trial. Generate Biomedicines highlighted that its Generate platform functions as an integrated "design-build-test-learn" closed-loop system, engineered to produce proprietary data and differentiated molecular solutions with therapeutic relevance. The company stated that the potential of its technology has been validated by three computationally designed proteins that have successfully entered human clinical trials. The most advanced candidate, GB-0895, is an investigational long-acting anti-thymic stromal lymphopoietin monoclonal antibody. Patient recruitment is currently underway for a key Phase III clinical trial targeting severe asthma. Founded in 2018 and headquartered in Somerville, Massachusetts, the company intends to list on the Nasdaq under the ticker symbol "GENB." Generate Biomedicines had confidentially filed for an IPO on December 23, 2025. The offering's joint book-running managers are Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald.